Matthew Oberley: Characterization of plasma cfDNA variants as of tumor- or clonal hematopoiesis-origin
Matthew Oberley, Chief Clinical Officer and Senior Vice President at Caris Life Sciences, shared a post on LinkedIn about a paper he co-authored with colleagues published in Clinical Cancer Research:
“Direct measurement of clonal hematopoiesis by sequencing avoids interference with interpretation of liquid biopsies in patients with solid tumors.
But at a larger level, discrimination as to the source of somatic variants in plasma by independent sequencing of the plasma and white cell compartments boosts signal-to-noise with applications like tumour-naive minimal residual disease testing and allows tumor-normal analysis from liquid biopsy for downstream therapy design.
I am very happy to see this Precision Oncology Alliance collaboration published in Clinical Cancer Research today.”
Authors: Daniel Magee, Valeriy Domenyuk, Jim Abraham, Matthew Oberley, Milan Radovich, David Spetzler et al.
More posts featuring Matthew Oberley.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023